ZURICH, June 22 (Reuters) - Novartis aims to help manufacture more than 50 million doses of BioNTech's COVID-19 vaccine in 2021 at its Stein, Switzerland fill-and-finish facility, the Swiss drugmaker said, after the European Union's drug regulator approved the bottling plant. (Reporting by John Miller Editing by Chris Reese)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
94.99 CHF | +0.52% | +4.12% | +11.92% |
12:53pm | AlphaValue/Baader Europe Lowers Price Target on Novartis, Maintains Add Recommendation | MT |
12:30pm | Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.92% | 216B | |
+43.42% | 749B | |
+39.42% | 605B | |
-6.47% | 351B | |
+19.44% | 328B | |
+8.80% | 292B | |
-2.62% | 214B | |
+0.39% | 167B | |
+6.73% | 165B | |
+1.39% | 123B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis : aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine in 2021